XtalPi Holdings said, in late June 2025, Shenzhen XtalPi Technology, an indirect subsidiary of the company, and DoveTree Medicines and its affiliates entered into a definitive agreement, under which the Group will use its end-to-end AI drug discovery platform through integrated AI + robotics technology to discover and develop small molecule and antibody drug candidates for multiple targets selected by DoveTree. The Group has received an initial payment of $51 million under the Definitive Agreement.
The Group is entitled to receive a further payment of $49 million, and is eligible to receive potential regulatory and commercial milestone payments, as well as potential royalties.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.